JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

A Review on Physicochemical Characteristics, Classification, Synthesis, Applications of Nanogels as Novel Drug Delivery Systems

Tekeshwar Kumar[1], Suraj Vishwas*[2], Sunil Sahu[1], Humaira Yasini[2], Dev Kumar[2], Diamond Sinha[2]

[1] *Department of Pharmaceutical Chemistry, Sanskar City College of Pharmacy, Thakurtola, Chhattisgarh, India*
[2] *Department of Pharmaceutics, Sanskar City College of Pharmacy, Thakurtola, Chhattisgarh, India*

Publication history: Received on 18th January 2026; Revised on 26th February 2026; Accepted on 27th February 2026

Article DOI: 10.69613/62s1ph93

Abstract: Nanogels are a class of three-dimensionally crosslinked polymeric networks that bridge the gap between macroscopic hydrogels and colloidal nanoparticles. These nanosized constructs possess unique features such as high-water content, mechanical flexibility, and a high surface area-to-volume ratio, facilitating the efficient encapsulation of diverse therapeutic payloads ranging from small molecules to biologics. The integration of stimuli-responsive elements allows for autonomous drug release in response to localized physiological triggers like pH gradients, redox potential, and enzymatic activity, thereby enhancing therapeutic index while minimizing systemic toxicity. Fabrication methods involving both top-down lithographic techniques and bottom-up chemical polymerization provide precise control over morphological and topological parameters. Despite superior performance in preclinical models for oncology, neurology, and inflammatory disorders, clinical transition faces hurdles including manufacturing scalability, potential immunogenicity of PEGylated surfaces, and the need for standardized regulatory pathways. Future advancements utilizing bioorthogonal chemistry and computational modeling are essential to refine the pharmacokinetic profiles of these systems. The maturation of nanogel technology signifies a shift toward personalized nanomedicine, where delivery platforms are tailored to specific pathological microenvironments to ensure optimal clinical outcomes.

Keywords: Nanogels; Stimuli-responsive polymers; Targeted delivery; Hydrogels; Nanobiotechnology.

1. Introduction

Nanocarriers are characterized by dimensions typically within the 1 to 1000 nm range which provide numerous biophysical benefits compared to traditional drug formulations [1]. These systems improve the solubility of hydrophobic pharmacological agents, facilitate drug accumulation in diseased tissues through the enhanced permeability and retention effect, and protect fragile therapeutics from chemical or enzymatic degradation [2]. Various platforms such as polymeric micelles, liposomes, and inorganic matrices have been investigated, yet hydrogel-based systems remain particularly attractive due to their biomimetic properties [3].

Nanogels are defined as discrete, nanosized, crosslinked polymeric networks that combine the high hydrophilicity and swelling capacity of bulk hydrogels with the colloidal advantages of nanoparticles [4]. These constructs are classified as polymeric nanoparticles and can be developed through the assembly of macromolecular precursors or the polymerization of low-molecular-weight monomers [5].

The structural stability of these systems is maintained through covalent bonds or physical interactions, such as hydrogen bonding and electrostatic forces, which prevent the network from dissolving while allowing it to absorb significant quantities of water [6]. This ability to retain a large volume of aqueous media without losing structural integrity is a result of the thermodynamic affinity of functional groups like hydroxyl and amide moieties within the polymer backbone [7]. Unlike linear polymers that dissolve upon hydration, the topological constraints of the crosslinks in nanogels ensure they remain intact, making them highly suitable for complex biomedical applications requiring sustained release and high biocompatibility [8]

* Corresponding author: Suraj Vishwas

2. Physicochemical Attributes of Nanogels

The performance of nanogel platforms is dictated by a specific set of physical and chemical properties that influence their stability, drug loading capacity, and interaction with biological systems.

2.1. Morphological and Surface Characteristics

The nanometric scale of these carriers results in an exceptionally high surface area-to-volume ratio, which is a primary factor in enhancing the solubility of poorly water-soluble drugs [9]. While spherical shapes are commonly produced through bottom-up techniques like precipitation polymerization, more complex and anisotropic geometries can be achieved using top-down methods such as nanomolding [10]. These varied architectures allow for the encapsulation of a wide range of bioactive molecules, including siRNA, vaccines, and antineoplastic agents [11]. The surface chemistry can be further modified to incorporate ligands for active targeting or polyethylene glycol (PEG) chains to prolong systemic circulation by avoiding detection by the mononuclear phagocyte system (MPS) [12].

2.2. Thermodynamics of Swelling and Network Integrity

Swelling is a fundamental behavior of nanogels that determines their drug release profiles. In neutral systems, the equilibrium swelling is a balance between the osmotic pressure of the polymer-solvent mixing and the elastic retractive force of the crosslinked network [2]. In polyelectrolyte systems, the ionization of pendant groups creates additional internal osmotic pressure, leading to more pronounced expansion [13]. Factors such as crosslink density, the hydrophilicity of the polymer, and environmental conditions like pH and ionic strength play critical roles in determining the final volume of the swollen gel [14]. A higher crosslink density generally restricts the expansion of the network, whereas changes in the surrounding ionic environment can shield charges and cause the gel to collapse or expand [15]. This reversible transition is essential for developing delivery systems that respond to specific physiological cues [3].

2.3. Biocompatibility and Mechanical Deformability

The high-water content of the nanogel matrix creates a low interfacial tension with biological fluids, which helps minimize non-specific protein adsorption and immune system activation [1]. Most nanogels are designed using biodegradable polymers that break down into non-toxic metabolic products [16]. Their mechanical flexibility is a significant advantage; unlike rigid inorganic nanoparticles, nanogels can deform to pass through pores or biological barriers that are smaller than their hydrodynamic diameter [5]. This deformability has been shown to reduce splenic sequestration and extend the time the particles remain in circulation, improving the likelihood of reaching the intended target site [6].

3. Systematic Classification of Nanogel Systems

Nanogels are categorized based on several structural and chemical parameters, which define their functional capabilities and therapeutic applications [17].

3.1. Classification by Polymer Composition

The chemical nature of the constituent polymers determines the surface charge, degradation rate, and biological interactions of the nanogel.

3.1.1. Polyacrylate and Polyester-Based Systems

Polyacrylate nanogels typically acquire a negative surface charge under physiological pH, facilitating osmotic swelling and counter-ion exchange [18]. In contrast, polyester and polyether-based systems, such as those incorporating polylactic acid (PLA), polyglycolic acid (PGA), or their copolymer PLGA, are valued for their biodegradability [19]. These polymers are linked via hydrolytically sensitive ester bonds. PLA, existing as L- and D-stereoisomers, exhibits different degradation rates, with the L-form being more susceptible to enzymatic hydrolysis [20].

3.1.2. Polyethylene Glycol and Amphiphilic Block Copolymers

PEG remains a standard component in nanomedicine due to its ability to form a hydration layer that inhibits opsonization and phagocytosis, thereby extending circulation half-life [21]. Poloxamers, or Pluronic™ resins, are amphiphilic ABA triblock

copolymers consisting of hydrophilic poly(ethylene oxide) (PEO) and hydrophobic poly(propylene oxide) (PPO). These systems are particularly effective at encapsulating hydrophobic drugs within their core while maintaining a stable, hydrophilic exterior [22].

3.1.3. Polysaccharide and Polypeptides

Polysaccharide-based nanogels, derived from natural sources like chitosan, alginate, or pullulan, offer excellent biocompatibility and biodegradability [23]. They contain numerous reactive functional groups that allow for further chemical modification. Polypeptide-based systems utilize repeating amide linkages, although they are more prone to proteolytic degradation *in vivo* [24].

Table 1. Classification and Functional Roles of Polymers in Nanogel Construction

Polymer Type	Examples	Functional Role and Benefits	References
Natural	Chitosan, Alginate, Hyaluronic acid	High biocompatibility, intrinsic bioadhesion, and enzymatic degradability.	[12, 23]
Synthetic	PNIPAM, Poly(acrylic acid), PEG	Precise control over crosslink density, tunable stimuli-responsiveness, and stealth properties.	[8]
Amphiphilic	Poloxamers (Pluronic), PEO-PPO-PEO	Self-assembly into core-shell structures for the encapsulation of hydrophobic payloads.	[22]
Biodegradable	PLA, PGA, PLGA	Controlled degradation via hydrolysis of ester linkages into non-toxic metabolic byproducts.	[19, 20]

3.2. Structure-Based Categorization

The topological arrangement of the polymer network influences drug loading and release mechanisms.

3.2.1. Core-Shell and Multi-layered Architectures

Core-shell nanogels consist of a distinct internal core surrounded by a shell of a different composition, allowing for surface-mediated drug release or protection of the payload [25]. Multi-layered or "onion-like" nanogels enable sequential drug release as concentric layers degrade at different rates [26].

3.2.2. Hollow and Hairy Nanogels

Hollow nanogels possess a solvent-filled internal cavity, significantly increasing the surface area for drug interaction and loading [27]. Hairy nanogels feature polymer chains grafted onto the surface, providing tunable steric stabilization and functional sites for ligand attachment [28].

3.3. Classification by Linkage Type

The nature of the crosslinks dictates the mechanical stability and reversibility of the nanogel network.

3.3.1. Physical and Non-covalent Interactions

Physically crosslinked nanogels are stabilized by reversible interactions such as hydrogen bonding, hydrophobic associations, or electrostatic forces [29]. While these systems can disassemble in response to environmental changes, they generally exhibit lower mechanical stability compared to covalent systems [30].

3.3.2. Chemical and Covalent Crosslinking

Chemically crosslinked nanogels are held together by permanent covalent bonds, offering superior structural integrity and predictable release kinetics [31]. These networks are often produced using crosslinking agents or radiation-induced polymerization to ensure a robust architecture [32].

3.4. Stimuli-Responsive Categories

"Smart" nanogels are engineered to undergo physical or chemical transitions when exposed to specific triggers.

3.4.1. Temperature and pH-Sensitive Systems

Thermoresponsive nanogels exploit polymers that exhibit a volume phase transition temperature (VPTT). Polymers like poly(N-isopropylacrylamide) (PNIPAM) collapse above their lower critical solution temperature (LCST), triggering drug expulsion [33]. pH-sensitive systems contain ionizable groups that protonate or deprotonate in response to the acidic microenvironment of tumors or endosomes, leading to network expansion and drug release [34].

3.4.2. Redox and Enzyme-Responsive Nanogels

Redox-sensitive nanogels often incorporate disulfide bonds that remain stable in circulation but are rapidly cleaved by intracellular glutathione (GSH) [35]. Enzyme-responsive systems utilize biodegradable sequences that are recognized by specific proteases or lipases overexpressed in pathological states [36].



Figure 1. Mechanism of Stimuli-Responsive Drug Release

Table 2. Stimuli-Responsive Mechanisms and Triggering Factors

Stimulus Type	Triggering Factor	Transition Mechanism	Typical Polymer/Moiety	References
Thermal	Temperature change (LCST/UCST)	Hydrophobic collapse or swelling of the network.	PNIPAM, Poly(vinyl caprolactam)	[33]
pH-Responsive	Acidic pH (Tumor/Endosome)	Protonation/Depronation leading to electrostatic repulsion.	Chitosan, Poly(acrylic acid)	[3, 34]
Redox	Glutathione (GSH) concentration	Cleavage of disulfide crosslinks within the matrix.	Cystamine-based crosslinkers	[35]
Enzymatic	Matrix Metalloproteinases (MMPs)	Site-specific biodegradation of peptide linkages.	MMP-sensitive peptide sequences	[14, 36]
Light	UV or NIR Irradiation	Photo-isomerization or photo-cleavage of chromophores.	Azobenzene, o-Nitrobenzyl groups	[37]

4. Fabrication Methods for Nanogels

The construction of nanogels involves either the fragmentation of larger materials or the assembly of molecular precursors.

4.1. Top-Down Fabrication Techniques

Top-down methods rely on physical or mechanical forces to generate nanoscale structures from bulk materials [37].

4.1.1. Photolithography and PRINT Technology

Photolithography uses UV light to crosslink polymers into precise three-dimensional patterns on silicon wafers [38]. The Particle Replication in Non-wetting Templates (PRINT) methodology is a refined version that allows for the production of nanogels with highly uniform dimensions and shapes, suitable for loading proteins or nucleic acids [39].

4.1.2. Micro-molding Strategies

Micro-molding involves depositing polymer precursors onto polydimethylsiloxane (PDMS) substrates, followed by UV-initiated crosslinking. This approach is often used to create cell-embedded microgels or shape-controlled delivery vehicles [40].

4.2. Bottom-Up Assembly Strategies

Bottom-up approaches assemble nanogels from monomers or polymer chains through controlled reaction conditions [41].

4.2.1. Free Radical and Controlled Radical Polymerization

Free radical polymerization (FRP) variants, such as precipitation or emulsion polymerization, are widely used due to their efficiency [42]. Controlled radical polymerization (CRP) techniques, including Atom Transfer Radical Polymerization (ATRP) and Reversible Addition-Fragmentation Chain-Transfer (RAFT), provide better control over the molecular weight and architecture of the resulting polymers [43].



Figure 2. Methods Used for Nanogel Fabrication

4.2.2. Self-Assembly and Physical Crosslinking

Polymer precursors can self-assemble in aqueous media via hydrophobic interactions or electrostatic complexation [44]. For example, cholesterol-bearing pullulan (CHP) spontaneously forms nanogels through hydrophobic associations, which can be modulated by cyclodextrins for controlled release [45].

Table 3. Comparison of Nanogel Fabrication Methods

Methodology	Approach	Advantages	Limitations	References
Photolithography	Top-down	Precise control over particle geometry and 3D architecture.	High equipment costs; limited to photo-crosslinkable polymers.	[38]
PRINT Technology	Top-down	Exceptional uniformity in size and shape; high batch fidelity.	Scalability challenges in large-scale industrial production.	[39]
Precipitation Polymerization	Bottom-up	Simple, surfactant-free process; high yields of spherical particles.	Sensitive to minor fluctuations in monomer concentration.	[42]
Micro-emulsion	Bottom-up	Ability to produce extremely small, sub-50 nm nanogels.	Requires significant quantities of surfactants and difficult purification.	[23]
Click Chemistry	Coupling	High selectivity and quantitative yields under mild conditions.	Potential toxicity of certain metal catalysts (e.g., Copper).	[46, 47]

4.3. Click Chemistry and Bioorthogonal Coupling

Click chemistry offers a highly efficient and selective route for nanogel formation under mild conditions [46]. Strategies like Copper-catalyzed Azide-Alkyne Cycloaddition (Cu-AAC) or strain-promoted alternatives (SPAAC) allow for the precise construction of networks without the need for toxic catalysts [47]. Thiol-ene reactions and Schiff base formations are also utilized to create acid-labile or redox-responsive linkages [48].

5. Analytical Strategies for Nanogel Characterization

The precise evaluation of the physicochemical properties of nanogels is essential to ensure their stability and functionality in biological environments [49].

5.1. Spectroscopic Confirmation of Network Formation

The structural integrity and chemical composition of nanogels are validated through a combination of spectroscopic techniques. Nuclear Magnetic Resonance (NMR) spectroscopy is frequently employed to elucidate the microenvironment of the polymer chains, allowing for the identification of specific resonance patterns in pH-sensitive or thermosensitive networks [50]. Fourier Transform Infrared (FTIR) spectroscopy serves as a critical tool for confirming the success of crosslinking reactions by monitoring the disappearance or emergence of characteristic functional group signals, such as amide or ester peaks [51]. Raman spectroscopy provides additional molecular symmetry data by measuring the inelastic scattering of monochromatic radiation, complementing infrared analysis in determining bond vibrations [50].

5.2. Morphological and Nanostructural Resolution

Visualizing the architecture of nanogels requires high-resolution microscopy. Scanning Electron Microscopy (SEM) generates topographical images that reveal the surface porosity and overall morphology [52]. For a more detailed view of the internal nanostructure, Transmission Electron Microscopy (TEM) is used, resolving features at the sub-nanometer scale [53]. Atomic Force Microscopy (AFM) offers quantitative three-dimensional data on particle dimensions and mechanical stiffness, providing insights into the deformability of the gels under physiological conditions [54].



Figure 3. Methods for Nanogel Characterization

5.3. Determination of Particle Dimensions and Stability

Dynamic Light Scattering (DLS) is the standard method for determining the hydrodynamic diameter and polydispersity index of nanogels in aqueous media [55]. Small-Angle Neutron Scattering (SANS) provides more complex structural details, such as mesh dimensions and crosslink density, by exploiting the interactions between neutrons and the polymer nuclei [50]. The colloidal stability of these systems is typically assessed through zeta potential measurements and accelerated flocculation assays in media that simulate the ionic strength and protein content of human plasma [51].

5.4. Evaluation of Encapsulation and Release Kinetics

Drug loading capacity and encapsulation efficiency are quantitatively measured using UV-Vis spectrophotometry or High-Performance Liquid Chromatography (HPLC) after separating the unentrapped drug from the nanogel matrix [56]. The release profiles are often studied using equilibrium dialysis or Franz diffusion cells, which simulate the movement of the therapeutic payload across biological membranes. These studies help in determining whether the drug release follows diffusion-controlled, swelling-mediated, or erosion-dependent mechanisms [57].

Table 4. Physicochemical Characterization Techniques

Characterization Parameter	Primary Analytical Technique	Information Derived	References
Hydrodynamic Diameter	Dynamic Light Scattering (DLS)	Particle size distribution and Polydispersity Index (PDI).	[55]
Internal Nanostructure	Transmission Electron Microscopy (TEM)	High-resolution resolution of core-shell layers and internal porosity.	[53]
Surface Functional Groups	FTIR / NMR Spectroscopy	Confirmation of crosslinking success and functional group integrity.	[50, 51]
Mechanical Properties	Atomic Force Microscopy (AFM)	Measurement of Young's Modulus and network deformability.	[54]
Thermal Behavior	Differential Scanning Calorimetry (DSC)	Determination of phase transition temperatures and network stability.	[2, 50]

6. Therapeutic Applications of Nanogel Platforms

The versatility of nanogels allows for their application across several medical fields, addressing challenges that traditional drug delivery systems cannot overcome [58].

6.1. Central Nervous System Targeted Delivery

Delivering therapeutics to the brain is hindered by the blood-brain barrier (BBB). Nanogels are uniquely suited for this task due to their small size and ability to be surface-modified with ligands that trigger receptor-mediated transcytosis [59]. For example, nanogels modified with specific peptides or antibodies have shown a significantly higher accumulation in the brain compared to free drug formulations, providing a promising route for treating glioblastomas and neurodegenerative disorders [60].

6.2. Precision Oncology and Antineoplastic Therapy

In cancer treatment, stimuli-responsive nanogels minimize off-target effects by releasing their cytotoxic payload only within the acidic or enzyme-rich tumor microenvironment [61]. pH-sensitive chitosan or polyacrylate systems have indicated improved efficacy against various solid tumors. Photodynamic nanogels that respond to specific wavelengths of light enable on-demand drug release and the generation of reactive oxygen species for synergistic chemo-photodynamic therapy [62].

Table 5. Targeted Therapeutic Applications of Nanogel Systems

Application Area	Payload Example	Nanogel Type	\Outcome	References
CNS Disorders	Cisplatin	PEG-b-PMAA (Modified)	Enhanced traversal of the BBB and reduction in glioblastoma volume.	[40, 60]
Oncology	Doxorubicin	pH-responsive Chitosan	Selective drug release in acidic tumor microenvironments; reduced cardiotoxicity.	[61]
Gene Therapy	siRNA	Cationic PEI Nanogels	Protection from nuclease degradation and efficient endosomal escape.	[63, 64]
Dermatology	Methotrexate	Chitin Nanogels	Improved dermal penetration and sustained release for psoriasis management.	[65]
Wound Healing	Curcumin	Collagen-HPMC Hybrid	Accelerated tissue regeneration and localized anti-inflammatory activity.	[17, 36]



Figure 4. Therapeutic Applications of Nanogels

6.3. Delivery of Labile Macromolecules and Nucleic Acids

Nanogels provide a protective scaffold for fragile biologics, such as siRNA, oligonucleotides, and proteins, shielding them from enzymatic degradation [63]. Cationic nanogels are particularly effective at complexing with negatively charged nucleic acids, facilitating their cellular internalization and escape from endosomes, which is a critical requirement for gene therapy [64].

6.4. Management of Inflammatory and Autoimmune Pathologies

The sustained release properties of nanogels are exploited in the treatment of chronic inflammatory conditions like psoriasis and arthritis [65]. Dermal applications of chitin or collagen-based nanogels have shown improved skin penetration and prolonged therapeutic concentrations of anti-inflammatory agents. Additionally, nanogels can be engineered to target activated macrophages, reducing the secretion of pro-inflammatory cytokines in autoimmune diseases [66].

6.5. Theranostic Systems and Antimicrobial Activity

Multifunctional nanogels integrate diagnostic and therapeutic capabilities into a single platform. By co-encapsulating imaging agents like Superparamagnetic Iron Oxide Nanoparticles (SPIONs) or quantum dots, researchers can monitor drug distribution in real-time using MRI or fluorescence imaging [67]. In the field of infectious diseases, nanogels enhance the local concentration of antibiotics at the site of infection while reducing systemic side effects, proving effective against broad-spectrum bacterial strains [68].

7. Comparative Advantages of Nanogel Platforms

Nanogels offer a distinct set of pharmacological and biophysical benefits that differentiate them from other nanocarrier classes, such as liposomes or solid lipid nanoparticles [69].

7.1. Intrinsic Biocompatibility and Network Resilience

The high aqueous content and low interfacial surface tension of nanogels minimize non-specific interactions with plasma proteins, which helps in avoiding the activation of the complement system [70]. Many formulations utilize polymers like hyaluronic acid or PEG, which are recognized for their low immunogenicity. Because these networks are three-dimensionally crosslinked, they maintain structural integrity during systemic circulation, preventing the premature disintegration often observed in non-crosslinked micellar systems [71].

7.2. Controlled Release and Payload Versatility

The crosslinked architecture allows for the precise modulation of drug release kinetics by adjusting the crosslink density and polymer chain length [72]. These parameters directly influence the mesh size of the network, which governs the diffusion rate of the

encapsulated agents. Nanogels are capable of simultaneous encapsulation of disparate therapeutic payloads. Hydrophilic agents are typically retained within the aqueous-rich interior through hydrogen bonding, while hydrophobic drugs can be sequestered within amphiphilic domains, facilitating the delivery of combination therapies [73].

7.3. Administration Compatibility and Deformability

Nanogels are compatible with various administration routes, including intravenous, pulmonary, and transdermal pathways [74]. Their mechanical deformability is a critical asset; these particles can change shape to navigate through physiological barriers or narrow capillaries that might otherwise trap rigid nanoparticles. This flexibility reduces the risk of embolism and facilitates deeper penetration into tumor tissues or the central nervous system [75].

8. Physicochemical and Biological Limitations

Despite their numerous benefits, several constraints hinder the universal application of nanogels in clinical settings [76].

8.1. Drug Loading and Release Constraints

Achieving high drug loading efficiency remains a challenge, particularly for molecules that do not have a strong thermodynamic affinity for the polymer matrix [77]. In some cases, the interaction between the drug and the polymer is too strong, leading to an irreversible collapse of the gel network. This collapse can immobilize the payload, preventing its release at the target site and reducing the overall bioavailability of the treatment [78].

8.2. Process-Related Impurities and Toxicity

The fabrication of nanogels often involves the use of surfactants, initiators, and crosslinking agents. If these components are not completely removed during purification, they may lead to cellular membrane disruption or inflammatory responses *in vivo* [79]. Residual monomers, such as acrylamide derivatives, are of particular concern due to their potential neurotoxicity and genotoxicity, necessitating rigorous validation of purification protocols [80].

9. Safety, Regulatory, and Clinical Obstacles

Transitioning nanogels from laboratory research to clinical implementation requires addressing significant biological and manufacturing hurdles [81].

9.1. Biological Barriers and Immune Recognition

While nanogels are designed to be stealthy, they are often sequestered by the mononuclear phagocyte system, particularly in the liver and spleen [82]. The formation of a protein corona—a layer of adsorbed serum proteins—can drastically alter the biological identity of the nanogel, leading to accelerated clearance. Although PEGylation is used to mitigate this, repeated administration can induce the production of anti-PEG antibodies, which may cause hypersensitivity reactions and reduced efficacy in subsequent doses [83].

9.2. Manufacturing Scalability and Quality Control

The large-scale production of nanogels with consistent physicochemical specifications is a major engineering obstacle [84]. Minor variations in temperature, stirring speed, or monomer concentration during construction can lead to significant batch-to-batch heterogeneity in size distribution and crosslink density. Achieving cGMP compliance requires advanced manufacturing technologies, such as microfluidics, to ensure the uniformity required for regulatory approval [85].

9.3. Regulatory Path and Toxicological Evaluation

Currently, there is no discrete regulatory framework dedicated specifically to nanogels, which complicates the investigational review process [86]. Attaining market authorization requires extensive preclinical data, including long-term chronic toxicity studies and detailed biodistribution profiles. The lack of standardized protocols for assessing the safety of "smart" materials that change their properties *in vivo* remains a significant gap in the current regulatory scenario [87].



Figure 5. Major Obstacles for Nanogels

10. Prospective Developments and Technological Frontiers

The trajectory of nanogel research is transitioning toward a more integrated approach that combines material science with computational intelligence and high-precision engineering [88].

10.1. Computational Modeling and Design Automation

The integration of artificial intelligence and machine learning into the design of nanogel formulations show a significant shift in pharmaceutical development. Researchers can model the compatibility between specific polymers and drug molecules by utilizing predictive algorithms, optimizing the crosslink topology to achieve desired release profiles [89]. This computational approach reduces the reliance on trial-and-error experimentation, allowing for the rapid identification of candidates with the highest potential for therapeutic success. Molecular dynamics simulations provide insights into how nanogels interact with biological membranes at the atomic level, informing the development of more effective targeting methods [90].

10.2. Bioorthogonal Chemistry and Personalized Medicine

The move toward personalized medicine is supported by the development of bioorthogonal chemistry, which allows for the assembly or modification of nanogels within biological systems without interfering with native biochemical processes [91]. This technology enables the creation of patient-specific delivery platforms that respond to unique biomarker profiles, such as specific enzyme concentrations or localized pH variations within a particular tumor [92]. By tailoring the responsiveness of the nanogel to the individual's pathological microenvironment, clinicians can achieve unprecedented levels of precision in drug delivery.

10.3. Innovations in Scalable Processing

To address the challenges of manufacturing, continuous-flow microfluidic technologies are being refined. These systems provide exceptional control over reaction kinetics and droplet dimensions, facilitating the production of nanogels with sub-10 nm size dispersity and high batch-to-batch fidelity [93]. The transition from batch processing to continuous manufacturing is essential for meeting cGMP standards and ensuring that these advanced platforms can be produced at the scale required for global clinical use [94].

11. Conclusion

Nanogels have emerged as a sophisticated and versatile class of polymeric carriers that successfully bridge the gap between macroscopic hydrogel properties and the requirements of colloidal nanomedicine. The evidence indicates that their unique three-dimensional architecture, high water content, and mechanical flexibility provide superior drug encapsulation and controlled release capabilities compared to traditional delivery systems. Their ability to respond to localized physiological cues such as pH gradients and enzymatic activity allows for site-selective therapy, which is particularly critical in oncology and neurology. However, the path to widespread clinical adoption is contingent upon overcoming significant hurdles related to manufacturing scalability, immune system recognition, and the establishment of clear regulatory pathways. The progress in bioorthogonal chemistry, microfluidic processing, and computational design is expected to address these limitations. As these technologies mature, nanogels are positioned to become a central component of precision medicine, offering a robust platform for the treatment of complex human diseases with minimized systemic toxicity and maximized therapeutic efficacy.

References

[1] Sultana F, Imran-Ul-Haque M, Arafat M, Sharmin S. An overview of nanogel drug delivery system. Journal of Applied Pharmaceutical Science. 2013;3(8):S95-105.

[2] Sharma A, Garg T, Aman A, et al. Nanogel—an advanced drug delivery tool: Current and future. Artificial Cells, Nanomedicine, and Biotechnology. 2016;44(1):165-77.

[3] Zhang H, Zhai Y, Wang J, Zhai G. New progress and prospects: The application of nanogel in drug delivery. Materials Science and Engineering: C. 2016;60:560-8.

[4] Yin Y, Hu B, Yuan X, et al. Nanogel: A versatile nano-delivery system for biomedical applications. Pharmaceutics. 2020;12(3):290.

[5] Scotti A, Schulte MF, Lopez CG, et al. How softness matters in soft nanogels and nanogel assemblies. Chemical Reviews. 2022;122(13):11675-700.

[6] Sasaki Y, Akiyoshi K. Nanogel engineering for new nanobiomaterials: from chaperoning engineering to biomedical applications. The Chemical Record. 2010;10(6):366-76.

[7] Ferozekhan S, Umashankar MS, Narayanasamy D, et al. A comprehensive review of nanogel-based drug delivery systems. Cureus. 2024;16(9):e68631.

[8] Kendre PN, Satav TS. Current trends and concepts in the design and development of nanogel carrier systems. Polymer Bulletin. 2019;76(3):1595-617.

[9] Srivastava S, Saha S, Jakhmola V. Nanogel: Types, Methods of Preparation, Limitation, Evaluation and Application—A Systematic Review. International Journal of Drug Delivery Technology. 2023;13:1631-9.

[10] Jain S, Ancheria RK, Shrivastava S, et al. An overview of nanogel–novel drug delivery system. Asian Journal of Pharmaceutical Research and Development. 2019;7(2):47-55.

[11] Neamtu I, Rusu AG, Diaconu A, et al. Basic concepts and recent advances in nanogels as carriers for medical applications. Drug Delivery. 2017;24(1):539-57.

[12] Altuntaş E, Özkan B, Güngör S, Özsoy Y. Biopolymer-based nanogel approach in drug delivery: basic concept and current developments. Pharmaceutics. 2023;15(6):1644.

[13] Vinogradov SV. Polymeric nanogel formulations of nucleoside analogs. Expert Opinion on Drug Delivery. 2007;4(1):5-17.

[14] Suhail M, Rosenholm JM, Minhas MU, et al. Nanogels as drug-delivery systems: A comprehensive overview. Therapeutic Delivery. 2019;10(11):697-717.

[15] Qureshi MA, Khatoon F. Different types of smart nanogel for targeted delivery. Journal of Science: Advanced Materials and Devices. 2019;4(2):201-12.

[16] Tiwari S, Singh S, Tripathi PK, Dubey CK. A review-nanogel drug delivery system. Asian Journal of Research in Pharmaceutical Science. 2015;5(4):253.

[17] Grimaudo MA, Concheiro A, Alvarez-Lorenzo C. Nanogels for regenerative medicine. Journal of Controlled Release. 2019;313:148-60.

[18] Kazakov S. Liposome-nanogel structures for future pharmaceutical applications: an updated review. Current Pharmaceutical Design. 2016;22(10):1391-413.

[19] Gupta J, Sharma G. Nanogel: A versatile drug delivery system for the treatment of various diseases and their future perspective. Drug Delivery and Translational Research. 2025;15(2):455-82.

[20] Maddiboyina B, Desu PK, Vasam M, et al. An insight of nanogels as novel drug delivery system with potential hybrid nanogel applications. Journal of Biomaterials Science, Polymer Edition. 2022;33(2):262-78.

[21] Zarekar NS, Lingayat VJ, Pande VV. Nanogel as a novel platform for smart drug delivery system. Nanoscience and Nanotechnology Research. 2017;4(1):25-31.

[22] Soni G, Yadav KS. Nanogels as potential nanomedicine carrier for treatment of cancer: A mini review of the state of the art. Saudi Pharmaceutical Journal. 2016;24(2):133-9.

[23] Attama AA, Nnamani PO, Onokala OB, et al. Nanogels as target drug delivery systems in cancer therapy: A review of the last decade. Frontiers in Pharmacology. 2022;13:874510.

[24] Ahmed S, Alhareth K, Mignet N. Advancement in nanogel formulations provides controlled drug release. International Journal of Pharmaceutics. 2020;584:119435.

[25] Hernandez-Adame L, Angulo C, Garcia-Silva I, et al. An overview of nanogel-based vaccines. Expert Review of Vaccines. 2019;18(9):951-68.

[26] Zhang X, Yan W, Song Z, et al. DNA nanogel for cancer therapy. Advanced Therapeutics. 2023;6(4):2200287.

[27] Singh N, Gill V, Gill P. Nanogel based artificial chaperone technology: an overview. American Journal of Advanced Drug Delivery. 2013;1(3):271-6.

[28] Mauri E, Giannitelli SM, Trombetta M, Rainer A. Synthesis of nanogels: Current trends and future outlook. Gels. 2021;7(2):36.

[29] Duan QY, Zhu YX, Jia HR, et al. Nanogels: synthesis, properties, and recent biomedical applications. Progress in Materials Science. 2023;139:101167.

[30] Rajput D, Singh M, Sahu P, et al. Advances in nanogel as drug delivery system for cancer therapeutics: an overview. Mini Reviews in Medicinal Chemistry. 2023;23(21):2053-72.

[31] Chacko RT, Ventura J, Zhuang J, Thayumanavan S. Polymer nanogels: a versatile nanoscopic drug delivery platform. Advanced Drug Delivery Reviews. 2012;64(9):836-51.

[32] Maya S, Sarmento B, Nair A, et al. Smart stimuli sensitive nanogels in cancer drug delivery and imaging: a review. Current Pharmaceutical Design. 2013;19(41):7203-18.

[33] Ali AA, Al Bostami RD, Al-Othman A. Nanogel-based composites for bacterial antibiofilm activity: advances, challenges, and prospects. RSC Advances. 2024;14(15):10546-59.

[34] Ma X, Li SJ, Liu Y, et al. Bioengineered nanogels for cancer immunotherapy. Chemical Society Reviews. 2022;51(12):5136-74.

[35] Hashimoto Y, Mukai SA, Sasaki Y, Akiyoshi K. Nanogel tectonics for tissue engineering: protein delivery systems with nanogel chaperones. Advanced Healthcare Materials. 2018;7(23):1800729.

[36] Wang H, Gao L, Fan T, et al. Strategic design of intelligent-responsive nanogel carriers for cancer therapy. ACS Applied Materials & Interfaces. 2021;13(46):54621-47.

[37] Anwar A, Teow SY, Wu YS. Nanogel-based drug delivery system as a treatment modality for diverse diseases: Are we there yet?. Journal of Drug Delivery Science and Technology. 2024;91:105224.

[38] Basu B, Mallick S, Dhauria S, et al. Native/modified dextran-based nanogel in delivering drug and management of ocular complications: a review. Zeitschrift für Naturforschung C. 2026;81(1-2):31-53.

[39] Pinelli F, Ortolà ÓF, Makvandi P, et al. *In vivo* drug delivery applications of nanogels: a review. Nanomedicine. 2020;15(27):2707-27.

[40] Vashist A, Kaushik A, Vashist A, et al. Nanogels as potential drug nanocarriers for CNS drug delivery. Drug Discovery Today. 2018;23(7):1436-43.

[41] Mauri E, Perale G, Rossi F. Systematic analysis of nanogel-based platforms for clinical application. Journal of Controlled Release. 2021;330:1102-14.

[42] Molina M, Asadian-Birjand M, Balach J, et al. Stimuli-responsive nanogels for the delivery of therapeutic agents. Chemical Society Reviews. 2015;44(17):6161-86.

[43] Kuckling D. Stimuli-responsive nanogels. Colloid and Polymer Science. 2009;287(8):881-91.

[44] Steinhilber D, Seidi F, Sanson N, et al. Nanogels: from synthesis to advanced biomedical applications. Chemical Society Reviews. 2016;45:3000-25.

[45] Morimoto K, Sasaki Y, Akiyoshi K. Nanogel tectonics: assembly of nanogels to build functional materials. Polymer Journal. 2015;47(2):74-81.

[46] Smeds KA, Grinstaff MW. Photocrosslinkable polysaccharides for in situ hydrogel formation. Journal of Biomedical Materials Research. 2001;54(1):115-21.

[47] Kolb HC, Finn MG, Sharpless KB. Click Chemistry: Diverse Chemical Function from a Few Good Reactions. Angewandte Chemie International Edition. 2001;40(11):2004-21.

[48] Baldwin AD, Kiick KL. Polysaccharide-modified synthetic polymeric biomaterials. Biopolymers. 2010;94(1):128-40.

[49] Oh JK, Drumright R, Siegwart DJ, Matyjaszewski K. The development of microgels/nanogels for drug delivery applications. Progress in Polymer Science. 2008;33(4):448-77.

[50] Raemdonck K, Demeester J, De Smedt S. Advanced nanogel engineering for drug delivery. Soft Matter. 2009;5(4):707-15.

[51] Das M, Mardyani S, Chan WC, Kumacheva E. Biofunctionalized pH-responsive microgels for cancer cell targeting. Advanced Materials. 2006;18(1):80-3.

[52] Kabanov AV, Vinogradov SV. Nanogels as pharmaceutical carriers: finite networks of infinite capabilities. Angewandte Chemie International Edition. 2009;48(30):5418-29.

[53] Motornov M, Sheparovych R, Lupitskyy R, et al. Stimuli-responsive colloidal systems from mixed brush-coated nanoparticles. Advanced Functional Materials. 2007;17(14):2307-14.

[54] Li J, Li X, Ni X, et al. Self-assembled supramolecular hydrogels formed by biodegradable PEO-PHB-PEO triblock copolymers and alpha-cyclodextrin for controlled drug delivery. Biomaterials. 2006;27(22):4132-40.

[55] Tamura A, Yui N. Polyrotaxane-based nanogels for the cytosolic delivery of therapeutic proteins. Biomaterials Science. 2014;2(11):1532-42.

[56] Bronich TK, Keifer PA, Shushakov V, et al. Self-assembly of block copoly(ethylene oxide-sodium methacrylate) and cationic surfactants. 1. Polyion complex micelles. Langmuir. 1997;13(7):2097-105.

[57] Lee AS, Gast AP, Butun V, Armes SP. Characterizing the shell of a shell-cross-linked micelle. Macromolecules. 1999;32(13):4302-10.

[58] Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16-20.

[59] Vinogradov SV, Bronich TK, Kabanov AV. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Advanced Drug Delivery Reviews. 2002;54(1):135-47.

[60] Kabanov AV, Gendelman HE. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Progress in Polymer Science. 2007;32(8-9):1054-82.

[61] Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology. 2007;2(12):751-60.

[62] Nomura S, Kondoh S, Ohmine S, et al. Photodynamic effect of protoporphyrin IX-loaded nanogels on cancer cells. Journal of Controlled Release. 2010;142(1):31-8.

[63] Oishi M, Nagasaki Y. Stimuli-responsive smart nanogels for nucleic acid delivery. Nanomedicine. 2010;5(3):451-68.

[64] Blackburn WH, Dickerson EB, Smith MH, et al. Peptide-functionalized nanogels for targeted siRNA delivery. Bioconjugate Chemistry. 2009;20(5):960-8.

[65] Saboktakin A, Tabatabaie RM, Maharramov A, Ramazanov MA. Synthesis and characterization of pH-dependent glycol chitosan and dextran sulfate nanoparticles for delivery of retinoic acid. International Journal of Biological Macromolecules. 2011;49(4):747-51.

[66] Larsson M, Hillberg AL, Tabrizian M. Chitosan-based particles for mucosal drug delivery. Progress in Polymer Science. 2013;38(10-11):1507-28.

[67] Lim EK, Kim T, Paik S, et al. Nanomaterials for theranostics: recent advances and future challenges. Chemical Reviews. 2015;115(1):327-94.

[68] Insua I, Majewski KR, Sikder S, et al. Nanogel-based antimicrobials: progress and challenges. Materials Horizons. 2017;4(5):741-65.

[69] Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery. 2005;4(2):145-60.

[70] Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. Nanoparticle PEGylation for imaging and therapy. Nanomedicine. 2011;6(4):715-28.

[71] Kim SW, Yi NW, Chung DJ. Biocompatibility of cross-linked poly(ethylene glycol) hydrogels. Korea Polymer Journal. 2001;9(3):149-55.

[72] Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and a possibility. Journal of Controlled Release. 2011;153(3):198-205.

[73] Hu X, Li D, Wang Y, et al. Dual-responsive nanogels for co-delivery of doxorubicin and methotrexate. Soft Matter. 2011;7(13):5941-6.

[74] Patel A, Cholkar K, Mitra AK. Recent developments in ophthalmic drug delivery. Therapeutic Delivery. 2013;4(1):49-72.

[75] Anselmo AC, Mitragotri S. Impact of particle elasticity on particle-based drug delivery systems. Advanced Drug Delivery Reviews. 2017;108:51-67.

[76] Ganta S, Devalapally H, Shahiwala A, Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. Journal of Controlled Release. 2008;126(3):187-204.

[77] Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818-22.

[78] Hoffman AS. Hydrogels for biomedical applications. Advanced Drug Delivery Reviews. 2012;64:18-23.

[79] Nel AE, Mädler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nature Materials. 2009;8(7):543-57.

[80] Smith MH, Lyon LA. Multifunctional nanogels for siRNA delivery. Accounts of Chemical Research. 2012;45(7):985-93.

[81] Hua S, de Matos MBC, Metselaar JM, Storm G. Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines. Frontiers in Pharmacology. 2018;9:790.

[82] Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for tumors and adverse biodistribution. Nature Biotechnology. 2015;33(9):941-51.

[83] Ishida T, Wang X, Shimizu T, et al. A step-by-step investigation of PEGylated liposome-induced accelerated blood clearance (ABC) phenomenon. Journal of Controlled Release. 2007;122(3):349-55.

[84] Desu PK, Vasam M, Challa VT, et al. Industrial perspectives and quality by design (QbD) approach for nanogel manufacturing. Journal of Pharmaceutical Innovation. 2023;18:112-25.

[85] Liu D, Zhang H, Fontana S, et al. Microfluidic-assisted fabrication of carriers for controlled drug delivery. Lab on a Chip. 2017;17(11):1856-83.

[86] Etheridge ML, Campbell SA, Erdman AG, et al. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine. 2013;9(1):1-14.

[87] Tinkle S, McNeil SE, Mühlebach S, et al. Nanomedicines: addressing the scientific and regulatory gap. Annals of the New York Academy of Sciences. 2014;1313:35-56.

[88] Mitragotri S, Anderson DG, Chen X, et al. Accelerating the Translation of Nanomedicine. ACS Nano. 2015;9(7):6644-54.

[89] Bannigan P, Aldeghi M, Bao Z, et al. Machine learning models to predict self-assembly and drug loading in nanocarriers. Advanced Drug Delivery Reviews. 2021;173:204-26.

[90] Lammertink RG, Hempenius MA, Vancso GJ. Nanostructured systems from computational modeling: from basic science to technology. Advanced Engineering Materials. 2006;8(5):331-45.

[91] Sletten EM, Bertozzi CR. Bioorthogonal chemistry: fishing for selectivity in a sea of functionality. Angewandte Chemie International Edition. 2009;48(38):6974-98.

[92] Prescher JA, Bertozzi CR. Chemistry in living systems. Nature Chemical Biology. 2005;1(1):13-21.

[93] Björnmalm M, Yan Y, Caruso F. Engineering and evaluating drug delivery particles in microfluidic devices. Journal of Controlled Release. 2014;190:139-49.

[94] Valencia PM, Farokhzad OC, Karnik R, Langer R. Microfluidic technologies for accelerating the clinical translation of nanoparticles. Nature Nanotechnology. 2012;7(10):623-9.